# Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

> **NCT03059992** · PHASE3 · COMPLETED · sponsor: **Scynexis, Inc.** · enrollment: 233 (actual)

## Conditions studied

- Invasive Candidiasis
- Mucocutaneous Candidiasis
- Coccidioidomycosis
- Histoplasmosis
- Blastomycosis
- Chronic Pulmonary Aspergillosis
- Allergic Bronchopulmonary Aspergillosis
- Invasive Pulmonary Aspergillosis
- Recurrent Vulvovaginal Candidiasis
- Other Emerging Fungi

## Interventions

- **DRUG:** Ibrexafungerp

## Key facts

- **NCT ID:** NCT03059992
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-01
- **Primary completion:** 2023-08-25
- **Final completion:** 2023-08-25
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059992, "Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03059992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*